Roivant Sciences (ROIV)
NASDAQ:ROIV
Top Page
Roivant Sciences
(NASDAQ:ROIV)
Select Model
Select Model
Rating:61Neutral
Price Target:
$29.00
▲(0.17% Upside)
Action:ReiteratedDate:04/02/26
ROIV scores as a moderate-risk biotech: strong balance-sheet positioning and a constructive clinical/regulatory catalyst setup (including Priority Review) support the score, but persistent losses and ongoing cash burn weigh heavily. Technicals are neutral-to-slightly constructive, while valuation remains pressured due to negative earnings and no dividend support.
Positive Factors
Low Leverage / Strong Balance Sheet
A very low debt-to-equity ratio (~2%) and sizeable equity provide lasting financial flexibility. This reduces solvency risk, supports multi-year clinical programs, funds operating losses without forced asset sales, and preserves optionality for M&A, buybacks, or milestone funding.
Negative Factors
Consistent Cash Burn
Persistent negative operating and free cash flows indicate the business is not yet self-funding R&D and commercialization. Even with sizable cash, continued burn increases reliance on one-time proceeds or financings and raises execution risk if clinical or commercial timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
A very low debt-to-equity ratio (~2%) and sizeable equity provide lasting financial flexibility. This reduces solvency risk, supports multi-year clinical programs, funds operating losses without forced asset sales, and preserves optionality for M&A, buybacks, or milestone funding.
Read all positive factors
Roivant Sciences (ROIV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.19B
Dividend YieldN/A
Average Volume (3M)5.59M
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth-83.82%
EPS Growth-109.22%
CountryUS
Employees908
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding715,701,100
10 Day Avg. Volume4,247,147
30 Day Avg. Volume5,592,392
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.56
Price to Sales (P/S)251.93
P/FCF Ratio-8.67
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.47K
Enterprise Value/Gross Profit1.61K
Enterprise Value/Ebitda-19.28
Forecast
1Y Price Target
$33.56Price Target Upside15.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$79.15M
Roivant Sciences Business Overview & Revenue Model
Company Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, h...
How the Company Makes Money
Roivant makes money primarily through biopharmaceutical revenue streams tied to its subsidiaries and partnered programs. Key sources include: (1) Product sales from commercial-stage subsidiaries (where Roivant consolidates results, revenue is reco...
Roivant Sciences Earnings Call Summary
Earnings Call Date:Feb 06, 2026
(Q3-2025)
| % Change Since: |
Next Earnings Date:Jul 01, 2026
Earnings Call Sentiment Positive
The call presented a highly positive clinical development narrative — most notably a strong Phase II win for brepocitinib in cutaneous sarcoidosis with large effect sizes, supportive PROs and clean safety — together with multiple fully enrolled studies and a strong cash position. Key risks discussed include the small size and baseline imbalances of the CS trial (requiring Phase III confirmation), ongoing litigation (Moderna jury trial), high operating expenses and uncertainties around regulatory timelines, pricing and competition. On balance, the breadth of positive clinical results, enrollment momentum, and financial runway outweigh the execution and regulatory/legal risks.Positive Updates
Strong Phase II efficacy in cutaneous sarcoidosis (brepocitinib)
Proof-of-concept, randomized (3:2:2) 16-week study (n=31) showed robust efficacy for brepocitinib 45 mg vs placebo with a placebo-adjusted CSAMI improvement of ~21.6 points (statistically significant). Key outcomes: 100% of patients on brepo 45 mg achieved ≥10-point CSAMI improvement (MCID = 5 points), 62% achieved CSAMI <5 (functional remission), separation from placebo observed as early as Week 4 and maintained through Week 16, consistent improvements on multiple PROs (Skindex-16, KSQ skin domain, patient global impression) and safety with no SAEs and only mild/moderate AEs.
Negative Updates
Small Phase II sample size and baseline imbalances
Cutaneous sarcoidosis POC study included only 31 patients across 15 sites. Management noted baseline imbalances (longer disease duration and more plaque‑predominant, treatment‑resistant morphology in the 45 mg arm versus 15 mg and placebo) that complicate cross‑arm comparisons and increase reliance on replication in larger Phase III trials.
Read all updates
Q3-2025 Updates
Positive
Negative
Strong Phase II efficacy in cutaneous sarcoidosis (brepocitinib)
Proof-of-concept, randomized (3:2:2) 16-week study (n=31) showed robust efficacy for brepocitinib 45 mg vs placebo with a placebo-adjusted CSAMI improvement of ~21.6 points (statistically significant). Key outcomes: 100% of patients on brepo 45 mg achieved ≥10-point CSAMI improvement (MCID = 5 points), 62% achieved CSAMI <5 (functional remission), separation from placebo observed as early as Week 4 and maintained through Week 16, consistent improvements on multiple PROs (Skindex-16, KSQ skin domain, patient global impression) and safety with no SAEs and only mild/moderate AEs.
Read all positive updates
Company Guidance
Management laid out a catalyst‑rich 2026: brepocitinib already has an NDA in dermatomyositis and a Phase III in cutaneous sarcoidosis will start this year after a 31‑patient Phase II that showed a placebo‑adjusted CSAMI delta of ~21.6 points (statistically significant), 100% of 45 mg patients achieved ≥10‑point improvement, 62% reached CSAMI <5, with separation vs placebo as early as Week 4 and no SAEs (all AEs mild/moderate); a pivotal NIU Phase III readout is expected in H2 2026; Phase IIb mosli (PH‑ILD) and IMVT‑1402 D2T RA studies are fully enrolled (IMVT‑1402 DTRA enrolled 170 v. planned 120) with data expected in H2 2026, POC reads in 1402 and CLE are planned this year, and the Moderna jury trial begins March 9; financials for the quarter were R&D $165M (adj. $147M), G&A $175M (adj. $71M), non‑GAAP net loss $167M and $4.5B cash, and management reiterated 9+ pivotal readouts and multiple potential commercial launches over the coming years.Roivant Sciences Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.31M | 29.05M | 32.71M | 61.28M | 55.29M | 23.80M |
| Gross Profit | 12.14M | 28.14M | 31.11M | 48.15M | 46.32M | 21.74M |
| EBITDA | -1.02B | -1.10B | -802.89M | -1.18B | -910.77M | -720.58M |
| Net Income | -809.24M | -171.98M | 4.35B | -1.01B | -845.26M | -809.23M |
Balance Sheet | ||||||
| Total Assets | 5.23B | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B |
| Cash, Cash Equivalents and Short-Term Investments | 4.53B | 4.89B | 6.54B | 1.68B | 2.06B | 2.13B |
| Total Debt | 207.44M | 100.17M | 499.75M | 481.40M | 283.89M | 244.98M |
| Total Liabilities | 251.14M | 249.74M | 773.95M | 782.02M | 523.70M | 527.69M |
| Stockholders Equity | 4.27B | 4.69B | 5.97B | 1.16B | 1.66B | 1.90B |
Cash Flow | ||||||
| Free Cash Flow | -766.86M | -844.05M | -766.65M | -856.08M | -695.16M | -557.94M |
| Operating Cash Flow | -759.10M | -839.45M | -765.27M | -843.39M | -677.73M | -552.14M |
| Investing Cash Flow | 257.62M | -1.77B | 5.20B | -44.27M | 303.30M | -31.70M |
| Financing Cash Flow | -13.39M | -1.22B | 419.36M | 499.46M | 306.79M | 456.26M |
Roivant Sciences Technical Analysis
Positive
28.95
Price Trends
27.31
Positive
24.52
Positive
19.41
Positive
Market Momentum
0.27
Negative
59.90
Neutral
86.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ROIV, the sentiment is Positive. The current price of 28.95 is above the 20-day moving average (MA) of 27.78, above the 50-day MA of 27.31, and above the 200-day MA of 19.41, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 59.90 is Neutral, neither overbought nor oversold. The STOCH value of 86.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ROIV.
Roivant Sciences Risk Analysis
Roivant Sciences disclosed 98 risk factors in its most recent earnings report. Roivant Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Roivant Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $8.03B | 25.45 | 92.67% | ― | 31.19% | 59.01% | |
70 Outperform | $4.46B | 36.27 | 15.25% | ― | 17.92% | -26.13% | |
69 Neutral | $11.96B | 12.74 | -8.82% | ― | 4.14% | -179.96% | |
65 Neutral | $8.69B | 60.28 | 4.10% | 0.54% | 3.85% | -48.17% | |
61 Neutral | $20.19B | -14.22 | -18.32% | ― | -83.82% | -109.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ROIV
Roivant Sciences
29.12
19.06
189.46%
CORT
Corcept Therapeutics
43.68
-25.91
-37.23%
HALO
Halozyme
67.31
6.03
9.84%
JAZZ
Jazz Pharmaceuticals
201.06
98.15
95.37%
TECH
Bio-Techne
58.66
7.89
15.53%
Roivant Sciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Roivant Advances Brepocitinib Program, Refocuses Autoimmune Portfolio
Negative
Apr 2, 2026
On April 2, 2026, Roivant announced that its subsidiary Priovant had launched a seamless Phase 2b/3 clinical program of brepocitinib in lichen planopilaris, a rare, highly morbid inflammatory scalp disorder with no FDA-approved therapies and an es...
Business Operations and StrategyStock BuybackLegal Proceedings
Roivant Subsidiary Reaches Major Global Patent Settlement
Positive
Mar 3, 2026
On March 3, 2026, Roivant’s subsidiary Genevant Sciences and partner Arbutus Biopharma reached a $2.25 billion global settlement with Moderna to resolve all U.S. and international patent litigation over Moderna’s use of their lipid nan...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Roivant’s Priovant Unit Gains FDA Priority Review for Brepocitinib
Positive
Mar 3, 2026
On March 3, 2026, Roivant subsidiary Priovant Therapeutics said the U.S. Food and Drug Administration accepted its New Drug Application for brepocitinib to treat dermatomyositis and granted the filing Priority Review. The FDA set a Prescription Dr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.